|
市場調査レポート
商品コード
1400504
嚢胞性線維症肺疾患の世界市場:薬剤タイプ別、投与経路別、流通チャネル別、地域別、国別の分析、市場考察、予測Global Cystic Fibrosis Lung Disease Market : Analysis By Drug Type, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast |
||||||
|
嚢胞性線維症肺疾患の世界市場:薬剤タイプ別、投与経路別、流通チャネル別、地域別、国別の分析、市場考察、予測 |
出版日: 2024年01月01日
発行: Azoth Analytics
ページ情報: 英文 250 Pages
納期: 即納可能
![]() |
世界の嚢胞性線維症肺疾患の市場規模は、2022年の107億5,000万米ドルから2029年末までに468億7,000万米ドルに達し、予測期間の2024年~2029年にCAGRで25.7%の成長が予測されています。
市場は治療介入の継続的な進歩によって後押しされています。製薬企業は革新的な治療法を前線に送り出すため、研究開発に多額の投資を行っています。さらに、遺伝子治療やCFTRモジュレーターのような新しい薬剤や治療法の登場は、嚢胞性線維症患者の治療情勢を著しく改善しています。これらの進歩は患者の予後を改善するだけでなく、市場全体の成長にも寄与しています。
さらに、医療従事者や患者の間で嚢胞性線維症に対する認識が高まっていることも、市場成長の重要な促進要因となっています。診断能力の向上と疾患教育への取り組みの強化は、早期発見と早期介入に寄与し、市場成長に寄与しています。
当レポートでは、世界の嚢胞性線維症肺疾患市場について調査し、市場規模と予測、地域とセグメントの分析、主な動向と機会などの情報を提供しています。
List of Tables
Table A1: Cystic fibrosis Therapeutics in the pipeline
Table A2: Cystic fibrosis Small molecule therapies and their targeted mutations
Table A3: Non-viral vectors commonly used for gene and drug delivery in CF patients
Table A4: United States Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A5: United States Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A6: United States Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A7: United States Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A8: United States Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A9: United States Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A10: Canada Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A11: Canada Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A12: Canada Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A13: Canada Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A14: Canada Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A15: Canada Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A16: Rest of Americas Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A17: Rest of Americas Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A18: Rest of Americas Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A19: Rest of Americas Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A20: Rest of Americas Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A21: Rest of Americas Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A22: Germany Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A23: Germany Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A24: Germany Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A25: Germany Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A26: Germany Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A27: Germany Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A28: United Kingdom Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A29: United Kingdom Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A30: United Kingdom Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A31: United Kingdom Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A32: United Kingdom Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A33: United Kingdom Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A34: France Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A35: France Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A36: France Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A37: France Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A38: France Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A39: France Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A40: Italy Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A41: Italy Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A42: Italy Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A43: Italy Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A44: Italy Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A45: Italy Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A46: Spain Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A47: Spain Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A48: Spain Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A49: Spain Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A50: Spain Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A51: Spain Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A52: Rest of Europe Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A53: Rest of Europe Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A54: Rest of Europe Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A55: Rest of Europe Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A56: Rest of Europe Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A57: Rest of Europe Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A58: China Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A59: China Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A60: China Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A61: China Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A62: China Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A63: China Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A64: Australia Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A65: Australia Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A66: Australia Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A67: Australia Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A68: Australia Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A69: Australia Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A70: India Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A71: India Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A72: India Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A73: India Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A74: India Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A75: India Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A76: Rest of Asia Pacific Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A77: Rest of Asia Pacific Cystic Fibrosis Lung Diseases Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A78: Rest of Asia Pacific Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A79: Rest of Asia Pacific Cystic Fibrosis Lung Diseases Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A80: Rest of Asia Pacific Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A81: Rest of Asia Pacific Cystic Fibrosis Lung Diseases Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A82: Vertex Pharmaceuticals Key Company Financials, 2020-2022
Table A83: GSK PLC Key Company Financials, 2020-2022
Table A84: Novartis Key Company Financials, 2020-2022
Table A85: Roche Key Company Financials, 2020-2022
Table A86: Bayer AG Key Financials, 2020-2022
Table A87: Gilead Sciences, Inc. Key Financials, 2020-2022
Azoth Analytics has released a research report titled "Cystic Fibrosis Lung Disease Market (2024 Edition)" which provides a complete analysis of the global Cystic Fibrosis Lung Disease industry in terms of market segmentation by Drug Type (CFTR Modulators, Bronchodilators, Mucolytics, Anti-infectives) and By Route of Administration (Oral, Inhalation, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel) for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.
The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Australia, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.
The research also assesses market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market's evolution. During the forecast period, 2024-2029, the Global Cystic Fibrosis Lung Disease market is expected to grow at a CAGR of 25.7%. The Global Cystic Fibrosis Lung Disease Market is expected to generate USD 46.87 Billion by the end of 2029, up from USD 10.75 Billion in 2022.
The cystic fibrosis lung disease market is propelled by continuous advancements in therapeutic interventions. Pharmaceutical companies are investing heavily in research and development to bring innovative treatments to the forefront. Moreover, the emergence of novel drugs and therapies, such as gene therapies and CFTR modulators, has significantly improved the treatment landscape for cystic fibrosis patients. These advancements not only enhance patient outcomes but also contribute to the overall growth of the market.
Additionally, the rising awareness of cystic fibrosis among healthcare professionals and patients is a significant driver for market growth. Improved diagnostic capabilities and increased disease education efforts contribute to early detection and intervention which is contributing to the market growth.